The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Noxafil 40 mg/ml oral suspension

Merck Sharp & Dohme BV,EU/1/05/320/001

Main Information

Trade NameNoxafil 40 mg/ml oral suspension
Active SubstancesPosaconazole
Dosage FormOral suspension
Licence HolderMerck Sharp & Dohme BV,
Licence NumberEU/1/05/320/001

Group Information

ATC CodeJ02AC Triazole derivatives
J02AC04 posaconazole


License statusAuthorised
Licence Issued25/10/2005
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0126-132-027
Interchangeable List DocumentPDF of Interchangeable List
« Back